SRPT is making big moves today. Find out why the stock is trading 10% higher:

Sarepta Therapeutics (SRPT) is trading 10% higher at $94.1 today. The stock is surging on it's seeking potential accelerated approval of it's drugs to fight muscular dystrophy. The company submitted a BLA (Biologics License Application) or SRP-9001 for it's gene therapy for Duchenne muscular dystrophy treatment.

The stock is outperforming peers on an otherwise rather glum day for stocks in the healthcare sector.

Sarepta Therapeutics has been trading between a 52-week high of $101.24 and a 52-week low of $61.28. The stock has a market cap of $8.23 Billion.

Sarepta Therapeutics Inc. is leading a revolution in precision genetic medicine and every day is an opportunity to change the lives of people living with raredisease. The Company has built an impressive position in Duchenne muscular dystrophy (DMD) and in gene therapies for limb-girdle muscular dystrophies (LGMDs), mucopolysaccharidosis type IIIA, Charcot-Marie-Tooth (CMT), and other CNS-related disorders, with more than 40 programs in various stages of development.